SoFi stock falls after announcing $1.5B public offering of common stock
Investing.com - Leerink Partners lowered its price target on Geron Corporation (NASDAQ:GERN) to $2.00 from $3.00 on Wednesday, while maintaining an Outperform rating on the stock. The biotech company currently trades at $1.10, having lost over 67% year-to-date and is now trading near its 52-week low of $1.09, according to InvestingPro data.
The research firm cited disappointing quarterly results for Geron’s Rytelo drug, which showed negative growth compared to the previous quarter. Leerink noted that while this decline was anticipated based on prescription trends, it still represented an "optical negative" in the earnings report.
Leerink acknowledged that Geron is taking steps to improve the drug’s market performance, including expanding its field force in the second quarter and implementing several leadership changes in recent months. However, the firm indicated these initiatives need more time to positively impact sales.
Despite the current challenges, Leerink maintained its Outperform rating, suggesting that Rytelo’s underperformance stems more from "poor early launch execution than innate flaws with the product." The firm also noted that Geron’s current valuation is "undemanding."
Leerink has reduced both its near-term and peak sales estimates for Rytelo as a result of the quarterly performance.
In other recent news, Geron Corporation reported its earnings for the third quarter of 2025, highlighting a revenue shortfall that has caught the attention of investors. The company achieved an earnings per share (EPS) of -$0.03, which was in line with analyst forecasts. However, revenue figures did not meet expectations, coming in at $47.2 million compared to the anticipated $54.49 million. This represents a 13.38% miss in revenue projections. The earnings report has led to increased scrutiny from investors, given the revenue miss despite meeting EPS expectations. While the company’s stock experienced a decline in pre-market trading, the focus remains on how Geron will address this revenue gap. These developments are crucial for stakeholders monitoring the company’s financial performance and strategic direction.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.